Cas13

Cas13. Cas13 is a class of ribonuclease enzymes belonging to the CRISPR-Cas adaptive immune system found in bacteria and archaea. Unlike the more widely known DNA-targeting systems like Cas9, Cas13 specifically targets and cleaves RNA molecules. Its discovery expanded the CRISPR toolkit beyond genome editing, enabling precise RNA manipulation and detection technologies with significant implications for biotechnology and molecular diagnostics.

Overview and Discovery

The Cas13 family, originally characterized as C2c2, was first identified through computational analysis of microbial genomes by a team led by Eugene Koonin at the National Institutes of Health. Its distinct ribonuclease activity was subsequently confirmed experimentally by researchers including Feng Zhang at the Broad Institute and Jennifer Doudna at the University of California, Berkeley. This work established Cas13 as the first known CRISPR system that exclusively targets RNA, a finding published in prominent journals like *Science* and *Nature*. The discovery opened new avenues for RNA-focused applications, distinguishing it from the DNA-editing functions of systems like Cas9 and Cas12.

Structure and Mechanism

Cas13 proteins, such as the well-studied Cas13a from Leptotrichia shahii, possess a unique structure with two HEPN domains that confer ribonuclease activity. Upon binding to a complementary crRNA guide sequence, the complex undergoes a conformational change to recognize a specific RNA target. A critical feature is its "collateral cleavage" activity; after binding its target, the activated enzyme non-specifically degrades any surrounding RNA molecules. This mechanism is analogous to the indiscriminate single-stranded DNA cleavage reported for Cas12a. The activation process has been elucidated through structural studies using techniques like cryo-electron microscopy conducted at institutions such as the University of California, San Francisco.

Applications in Biotechnology

The collateral cleavage activity of Cas13 has been harnessed for highly sensitive RNA detection platforms, most notably SHERLOCK, developed by teams at the Broad Institute. This technology allows for the detection of pathogen RNA, such as from the Zika virus or SARS-CoV-2, with attomolar sensitivity and has been deployed in field settings. Furthermore, Cas13 is used for precise RNA knockdown in eukaryotic cells, offering a reversible alternative to DNA editing for modulating gene expression. Companies like Sherlock Biosciences are commercializing these tools for molecular diagnostics. Research at the Wyss Institute for Biologically Inspired Engineering has also explored its use in live-cell RNA imaging and therapeutic RNA editing.

Comparison with Other CRISPR Systems

Cas13 is distinct from the DNA-targeting Cas9 system, which creates double-strand breaks in chromosomal DNA and is widely used for genome editing in organisms from *Drosophila* to humans. While Cas12 also exhibits collateral cleavage, it targets DNA. The RNA-specificity of Cas13 aligns it more closely with functions of the RNA interference pathway, but with programmable guide RNAs. Systems like Cas3 are known for processive DNA degradation, and Cas10 is involved in type III CRISPR systems that can target both RNA and DNA. Each system, discovered through efforts at institutions like the University of Copenhagen and the Massachusetts Institute of Technology, has unique advantages for different biotechnological applications.

Challenges and Limitations

A primary challenge with Cas13 is controlling its potent collateral RNA cleavage activity, which can lead to cytotoxicity in eukaryotic cells and confound certain experimental results. Its delivery into cells for therapeutic applications faces hurdles common to macromolecule delivery, including the need for efficient viral vectors like adeno-associated virus. Furthermore, the large size of some Cas13 orthologs can complicate packaging. Off-target effects on the transcriptome remain a concern, driving research at places like the Stanford University School of Medicine to engineer high-fidelity variants. There are also ongoing investigations into its natural role in bacterial immunity against RNA phages like MS2 to better understand its evolution and potential biosafety implications.

Category:CRISPR Category:RNA Category:Enzymes